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Experimental section 
 
Fig. S1 Synthesis of compounds BG1-BG3 (7-9) 
 
 
Fig. S2 Synthesis of the compound BG4 (13) 
 
 
Instrumentation 
Dry-flash chromatography was performed on SiO2 (0.018–0.032 mm). Melting points were 
determined on a Boetius PMHK apparatus and were not corrected. IR spectra were recorded 
on a Thermo-Scientific Nicolet 6700 FT-IR Diamond Crystal. NMR: 1H and 13C NMR 
spectra were recorded on a Bruker Ultrashield Advance III spectrometer (at 500 and 125 
MHz, respectively) in the indicated solvent using TMS as the internal standard. Chemical 
shifts are expressed in parts per million (ppm) on the (δ) scale, and coupling constants (J) in 
Hz. ESI MS spectra of the synthesized compounds were recorded on an Agilent 
Technologies 6210 Time-of-Flight LC/MS instrument in positive ion mode using 
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MeOH/H2O = 1:1 with 0.2% HCOOH as the carrying solvent solution. The samples were 
dissolved in pure MeOH (HPLC grade). The selected values were as follows: capillary 
voltage = 4 kV; gas temperature = 350 °C; drying gas N2 = 12 L/min; nebulizer pressure = 
45 psig; fragmentator voltage = 70 V.  All the yields reported refer to isolated yields. 
GC‒MS spectra of the synthesized compounds were acquired on an Agilent Technologies 
7890A apparatus equipped with a DB-5 MS column (30 m × 0.25 mm × 0.25 μm), a 5975C 
MSD and FID detector. The selected values are as follows: carrier gas was He (1.0 
mL/min), temperature linearly increased from 40–315 °C (10 °C/min), injection volume = 1 
μL, temperature = 250 °C, temperature (FID detector) = 300 °C, and EI mass spectra range: 
m/z 40–550. Compounds were analyzed for purity using: Agilent 1200 HPLC system 
equipped with Quat Pump (G1311B), Injector (G1329B) 1260 ALS, TCC 1260 (G1316A) 
and Detector 1260 DAD VL+(G1315C), and Waters 1525 HPLC dual pump system 
equipped with an Alltech Select degasser system, and a dual λ 2487 UV–VIS detector. All 
compounds were >95% pure. Method A: Zorbax Eclipse Plus C18 4.6 × 150 mm, 1.8μ, S.N. 
USWKY01594 was used as the stationary phase. Eluent was made from the following 
solvents: 0.2% formic acid in water (A) and acetonitrile (B). The analysis was performed at 
the UV max of the compounds to maximize selectivity. Compounds were dissolved in 
methanol, final concentrations were 1 mg/mL. Flow rate was 0.5 mL/min. Compounds 7-9 
and 13 were eluted using gradient protocol: 0 – 0.5 min 95%A, 0.5 - 3 min 95%A→ 5%A, 3 
- 13 min 5%A, 13 – 14 min 5%A→ 95%A, 14 – 16 min 95%A. Method B: Poroshell 120 
EC-C18 4.6 × 50mm, 2.7μ, S.N. USWKY01594 was used as the stationary phase. Eluent 
was made from the following solvents: 0.2% formic acid in water (A) and acetonitrile (B). 
The analysis were performed at the UV max of the compounds to maximize selectivity. 
Compounds were dissolved in methanol, final concentrations were 1 mg/mL. Flow rate was 
0.5 mL/min. Compounds 7-9 and 13 were eluted using gradient protocol: 0 – 0.5 min 
95%A, 0.5 - 3 min 95%A→ 5%A, 3 - 13 min 5%A, 13 – 14 min 5%A→ 95%A, 14 – 16 
min 95%A. 
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General procedure for Suzuki coupling reactions 
 
5-(4-Formylphenyl)thiophene-2-carbaldehyde (4)1 
S
H
O
O
H  
To a dry glass flask purged with argon were added Pd(OAc)2 (2.9 mg, 0.013 mmol), PPh3 
(14 mg, 0.050 mmol) and dry DME (2 mL). The resultant solution was stirred at room 
temperature for 10 min, and 5-bromothiophene-2-carbaldehyde 1 (30 µL, 0.26 mmol) and 
Na2CO3 (aq) (2M, 0.30 mL, 0.6 mmol) were added. After 5 min, 4-formylphenylboronic 
acid (49 mg, 0.33 mmol) was added and the reaction mixture was purged with argon and 
refluxed at 90 ºC for 3 h under argon. The solution was cooled to room temperature and 
filtered through a pad of Celite, washed with CH2Cl2 and dried with anhydrous Na2SO4. The 
organic solvent was removed under reduced pressure and the crude product was purified by 
dry-flash chromatography (SiO2: hexane/EtOAc = 9:1 to 6:4) to afford the title compound 4 
(54 mg, 96%) as a yellow amorphous powder, mp = 130‒132 oC. IR (ATR): 3078, 3047, 
2844, 2757, 1693, 1658, 1601, 1566, 1506, 1447, 1396, 1318, 1291, 1224, 1183, 1059, 961, 
840m, 806, 761, 696, 675 cm-1. 1H NMR (500 MHz, CDCl3): δ 10.06 (s, 1H), 9.95 (s, 1H), 
7.99-7.94 (m, 2H), 7.88-7.83 (m, 2H), 7.80 (d, J = 4.0 Hz, 1H), 7.55 (d, J =4.0 Hz, 1H) 
ppm. 13C NMR (125 MHz, CDCl3): δ 191.2, 182.8, 151.8, 144.0, 138.5, 137.1, 136.5, 130.5, 
126.8, 125.7 ppm. GC/MS (m/z(%)): 214.9 ([M]+, 100). 
 
1-[5-(4-acetylpheniyl)thiophen-2-yl]ethanone (5) 
S
O
O
 
Following the general procedure for Suzuki coupling, compound 2 (100 mg, 0.450 mmol) 
was transformed to the title compound 5 (109 mg, 92%) using 4-acylphenylboronic acid 
(100 mg, 0.610 mmol), Pd(OAc)2 (5.5 mg, 0.024 mmol) and PPh3 (26 mg, 0.097 mmol). 
The crude product was purified by dry-flash chromatography (SiO2: hexane/EtOAc = 8:2 to 
6:4) to afford the title compound 5 as a yellow amorphous powder, mp = 140‒144 oC. IR 
(ATR): 3332, 3291, 3076, 3051, 3028, 3003, 2962, 2919, 2857, 2708, 1676, 1655, 1600, 
1561, 1533, 1503, 1446, 1406, 1357, 1314, 1270, 1188, 1120, 1076, 1040, 959, 930, 832, 
754, 590 cm -1. 1H NMR (500 MHz, CDCl3): δ 8.03-7.98 (m, 2H), 7.78-7.72 (m, 2H), 7.69 
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(d, J = 4.0 Hz, 1H),7.43 (d, J = 4.0 Hz, 1H),2.63 (s, 3H), 2.59 (s, 3H) ppm. 13C NMR (125 
MHz, CDCl3): δ 197.1, 190.5, 150.7, 144.4, 137.5, 136.9, 133.3, 129.1, 126.2, 125.2, 26.6 
ppm. GC/MS (m/z(%)): 244.0 ([M]+, 100). 
 
5-(4-formylphenyl)furan-2-carbaldehyde (6) 
O
O
HH
O
 
Following the general procedure for Suzuki coupling, compound 3 (100 mg, 0.570mmol) 
was transformed to the title compound 6 (101.3 mg, 88%) using 4-formylphenylboronic acid 
(107 mg, 0.710 mmol), Pd(OAc)2 (6.4 mg, 0.028 mmol) and PPh3 (30 mg, 0.11 mmol). The 
crude product was purified by dry-flash chromatography (SiO2: hexane/EtOAc = 8:2 to 3:7) 
to afford the title compound 6 as an orange amorphous powder, mp = 138‒140 oC. IR 
(ATR): 3113, 3060, 2862, 2827, 2738, 1675, 1603, 1527, 1487, 1425, 1391, 1362, 1315, 
1294, 1258, 1215, 1172, 1047, 967, 922, 834, 808, 779, 687 cm -1. 1H NMR (500 MHz, 
CDCl3): δ 10.04 (s, 1H), 9.71 (s, 1H), 8.00-7.95 (m, 4H), 7.35 (d, J = 3.5 Hz, 1H), 7,01(d, J 
=4.0 Hz, 1H) ppm. 13C NMR (125 MHz, CDCl3): δ191.3, 177.5, 157.5, 152.7, 136.5, 134.1, 
130.3, 125.6, 110.0 ppm. GC/MS (m/z(%)): 200.0 ([M]+, 100). 
 
4-(5-bromo-1,3-thiazol-2-yl)benzaldehyde (11) 
S
N
BrO
H  
To a dry glass flask purged with argon were added Pd(OAc)2 (12 mg, 0.050 mmol), PPh3 
(55 mg, 0.21 mmol) and dry DME (7 mL). The resultant solution was stirred at room 
temperature for 10 min and 2-bromo-1,3-thiazole (10) (172 mg, 1.05 mmol) and Na2CO3 
(aq) (2M, 1 mL, 2 mmol) were added. After 5 min of stirring at room temperature, 4-
formylphenylboronic acid (196 mg, 1.31 mmol) was added and the reaction mixture was 
purged with argon and refluxed at 90 ºC for 3 h under argon. The solution was cooled to 
room temperature and filtered through a pad of Celite, washed with CH2Cl2 and dried with 
anhydrous Na2SO4. The organic solvent was removed under reduced pressure and the crude 
product was purified by dry-flash chromatography (SiO2: hexane/EtOAc = 9:1 to 7:3). The 
solvent was removed under reduced pressure, the crude product was dissolved in 1,2-
dichlorethane (1.2 mL) and a solution of bromine (30 L, 0.52 mmol) in 1,2-dichlorethane 
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(1.2 mL) was added. The reaction mixture was stirred at room temperature for 18 h. The 
reaction was stopped with the addition of saturated Na2S2O3 (aq) (5 mL), washed with 
CH2Cl2 and dried with anhydrous Na2SO4.The organic solvent was removed under reduced 
pressure and the crude product was purified by dry-flash chromatography (SiO2: 
hexane/EtOAc = 8:2 to 3:7) to afford the title compound 11 (44 mg, 16%) as a white 
amorphous powder, mp = 129 oC. IR (ATR): 3987, 3920, 2848, 2744, 1699, 1605, 1570, 
1477, 1422, 1266, 1211, 1173, 1106, 972, 827 cm -1. 1H NMR (500 MHz, CDCl3): δ 10.06 
(s, 1H), 8.09-8.01 (m, 2H), 7.99-7.93 (m, 2H), 7.82 (s, 1H) ppm. 13C NMR (125 MHz, 
CDCl3): δ191.3, 167.6, 145.6, 138.0, 137.3, 130.4, 126.7, 110.5 ppm. GC/MS (m/z (%)): 
268.9 ([M]+, 100). 
 
4,4'-(1,3-thiazole-2,5-diyl)dibenzaldehyde (12) 
S
N
H
O
H
O
 
Following the general procedure for Suzuki coupling, compound 11 (118 mg, 0.440 mmol) 
was transformed to the title compound 12 (35 mg, 27%) using 4-formylphenylboronic acid 
(82 mg, 0.55mmol), Pd(OAc)2 (5 mg, 0.02 mmol) and PPh3 (23 mg, 0.09 mmol). The crude 
product was purified by dry-flash chromatography (SiO2: hexane/EtOAc = 7:3 to 1:9) to 
afford the title compound 12 as a yellow amorphous powder, mp = 178‒180 oC. IR (ATR): 
3370, 2955, 2920, 2851, 1738, 1701, 1602, 1462, 1428, 1389, 1287, 1212, 1168, 1107, 823 
cm -1. 1H NMR (500 MHz, CDCl3): δ 10.08 (s, 1H), 10.05 (s, 1H), 8.23 (s, 1H), 8.20-8.12 
(m, 2H), 8.15-7.90 (m, 4H), 7.85-7.75 (m, 2H) ppm. 13C NMR (125 MHz, CDCl3): δ 191.4, 
191.2, 166.8, 141.4, 139.4, 138.3, 137.3, 136.7, 136.0, 130.6, 130.4, 127.1, 127.0 ppm. 
GC/MS (m/z (%)): 292.9 ([M]+, 100). 
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General procedure for preparation of guanylhydrazones 7-9 and 13 
 
(2E)-2-[(5-{4-[(E)-2-Carbamimidoylhydrazinylidene)methyl]phenyl}thiophen-2-
yl)methylidene]hydrazinecarboximidamide dihydrochloride (7, BG1)1 
S H
N
N
H
N
H
NH2
NH
N
H
NH2
NH
2HCl
 
To a solution of aldehyde 4 (20 mg, 0.092 mmol) in absolute ethanol (6 mL) 
aminoguanidine hydrochloride (26 mg, 0.23 mmol) was added. The resultant solution was 
stirred at room temperature for 5 min, and solution of concentrated HCl in absolute EtOH 
(40µL, 1:25 v/v) was added. The reaction mixture was heated to reflux for 18 h and allowed 
to cool to room temperature. The solvent was removed under reduced pressure, and the 
crude product was washed with CH2Cl2 (1 mL) and then crystallized from EtOH/hexane 
(9:1) to provide the title compound 7 (37 mg, 100%) as a pale-yellow solid, mp = 248‒250 
oC. IR (ATR): 3352, 3275, 3153, 2872, 1668, 1612, 1536, 1437, 1350, 1237, 1181, 1141, 
1011, 829 cm-1. 1H NMR (500 MHz, CD3OD): δ 8.30 (s, 1H), 8.15 (s, 1H), 7.86 (d, 2H, J = 
8.0 Hz), 7.78 (d, 2H, J = 8.0 Hz), 7.52 (d, 1H, J = 4.0 Hz), 7.45 (d, 1H, J = 4.0 Hz) ppm. 13C 
NMR (125 MHz, CD3OD): δ 157.3, 157.0, 148.8, 148.3, 144.1, 139.1, 137.2, 134.8, 134.3, 
129.7, 127.3, 126.0 ppm. (+)ESI-HRMS (m/z): [M+H]+ 329.12823 (error -2.77 ppm). HPLC 
purity: method A: RT 6.322, area 99.08%; method B: RT 2.544, area 95.62%. 
 
(2E)-2-[1-(5-{4-[(1E)-1-(2-carbamimidoylhydrazinylidene)ethyl]phenyl}thiophen-2-
yl)ethylidene]hydrazinecarboximidamide dihydrochloride (8, BG2) 
S
N
N NH
NH2
NH
N
H
NH2
NH
2HCl  
Following the general procedure for guanylhydrazone formation, compound 5 (100 mg, 
0.410 mmol) was transformed to the title compound 8 (76 mg, 44%) using aminoguanidine 
hydrochloride (113 mg, 1.02 mmol). The product was obtained as a pale-yellow solid, mp = 
226‒228 oC. IR (ATR): 3137, 1674, 1619, 1463, 1409, 1372, 1311, 1133, 835, 585 cm-1. 1H 
NMR (500 MHz, CD3OD): δ 8.00-7.95 (m, 2H), 7.78-7.74 (m, 2H), 7.55 (d, J = 4.0 Hz, 
1H), 7.48 (d, J = 4.0 Hz, 1H), 2.40 (s, 3H), 2.39 (s, 3H) ppm. 13C NMR (125 MHz, d-
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DMSO): δ 158.1, 157.7, 153.0, 150.1, 147.0, 143.4, 138.4, 136.3, 132.0, 129.6, 127.2, 
126.9, 17.0, 16.5 ppm. (+)ESI-HRMS m/z: [M + H]+ 357.16018 (error -0.72 ppm). HPLC 
purity: method A: RT 6.324, area 99.18%; method B: RT 2.640, area 95.32%. 
 
 (2Z)-2-(4-{5-[(E)-(2-carbamimidoylhydrazinylidene)methyl]furan-2-
yl}benzylidene)hydrazinecarboximidamidedihydrochloride (9, BG3) 
O
H
N N
H
NH2
NH
N
H
N
H
NH2
NH
2HCl  
Following the general procedure for guanylhydrazone formation, compound 6 (70 mg, 
0.35mmol) was transformed to the title compound 9 (135 mg, 100%) using aminoguanidine 
hydrochloride (97 mg, 0.87 mmol). The product was obtained as an orange solid, mp = 186 
oC. IR (ATR): 3326, 1673, 1617, 1277, 1226, 1141, 1025, 789 cm-1. 1H NMR (500 
MHz,CD3OD): δ 8.14 (s, 1H), 8.06 (s, 1H), 7.93-7.82 (m, 4H), 7.10-7.05 (m, 2H) ppm. 13C 
NMR (125 MHz, D2O): δ 154.5, 153.8, 153.6, 146.6, 136.2, 131.2, 129.6, 126.9, 123.3, 
118.5, 108.6 ppm. (+)ESI-HRMS m/z: [M + H]+ 313.15171 (error -0.86 ppm). HPLC purity: 
method A: RT 6.328, area 97.71%; method B: RT 2.518, area 96.31%. 
 
(2E)-2-[4-(2-{4-[(Z)-(2-carbamimidoylhydrazinylidene)methyl]phenyl}-1,3-thiazol-5-
yl)benzylidene]hydrazinecarboximidamide (13, BG4)  
S
N
H
N
H
N N
H
NH2
NH
N
H
NH2
NH
ClH2
 
Following the general procedure for guanylhydrazone formation, compound 12 (30 mg, 0.10 
mmol) was transformed to the title compound 13 (38 mg, 77%) using aminoguanidine 
hydrochloride (28 mg, 0.26 mmol). The product was obtained as a bright-yellow solid, mp = 
230‒231 oC. IR (ATR): 3363, 3265, 3131, 2952, 2919, 2877, 2803, 1672, 1622, 1540, 1486, 
1428, 1352, 1235, 1183, 1150, 867, 715 cm-1. 1H NMR (500 MHz, d-DMSO): δ 12.20-
12.00 (m, 2H), 8.49 (s, 1H), 8.24 (s, 1H), 8.22 (s, 1H), 8.10-7.90 (m, 4H), 7.99-7.94 (m, 
2H), 7.85-7.80 (m, 2H) ppm. 13C NMR (125 MHz, d-DMSO): δ 165.6, 155.4, 146.0, 145.9, 
141.2, 138.7, 135.2, 134.2, 133.5, 132.4, 128.5, 128.4, 126.6, 126.3 ppm. (+)ESI-HRMS 
m/z: [M + H]+ 406.15468 (error -2,48 ppm). HPLC purity: method A: RT 6.312, area 
99.05%; method B: RT 2.667, area 96.62%.  
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Fig. S3 In-vitro interaction of BG1-4 with pUC19 plasmid DNA. (M = molecular marker 
peqGOLD 1 kb DNA-Leiter Plus; C = DMSO treatment) 
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Fig. S4 BG1, BG2 and BG4 interaction with DNA. CD spectra (a, c, e) and molecular 
modeling (b, d, f). 
  
11 
 
 
Fig. S5 BG3 effect on the activity of C. albicans (a) mitochondrial dehydrogenses and (b) 
glutathione reductase and catalase. DMSO treated cells were used as control. 
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Fig. S6 BG3 effect on the C. albicans adhesion in the epithelial infection model. 
 
 
 
Table S1. FACS Analysis of apoptotic markers in C. albicans treated with BG3 and AmB 
 Annexin V+/PI- (%) Annexin V+/PI+ (%) Annexin V-/PI+ (%) 
Control 1.8 3.5 1.8 
BG3 2.8 6.6 3.8 
AmB 2.9 5.5 1.6 
 
 
 
Table S2. FACS Analysis of oxidative stress markers in C. albicans treated with BG3 and 
AmB 
 ROS (%) JC-1 (%) 
Control 0.1 1.2 
BG3 0.4 4.3 
AmB 9.2 44.1 
2MIC BG3 6.1 17.1 
2MIC AmB 27.8 / 
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